GlassScriptPhysician profile
In Kwon Park
NPI 1255588679
$1,910.83
in general payments reported to CMS, 2019-2025
18 companies · $768 in 2025
The $768 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.17 · 2021: $35.37 · 2022: $34.75 · 2023: $520 · 2024: $516 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,786 · Education: $18.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,786.18 |
| Education | $18.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $414.19 | 2023-2025 | Repatha, Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $293.90 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $233.83 | 2023-2024 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.52 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $109.41 | 2023-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $93.48 | 2023-2025 | Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.81 | 2024-2025 | Xifaxan, Trulance |
| Abbvie INC. | $80.43 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $78.67 | 2024-2025 | Gemtesa |
| Corium, LLC | $71.56 | 2023 | Adlarity |
| Bayer Healthcare Pharmaceuticals INC. | $70.31 | 2025 | |
| Janssen Pharmaceuticals, INC | $63.82 | 2023 | Spravato |
| Allergan, INC. | $36.17 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $25.80 | 2023 | Evkeeza |
| Amarin Pharma, INC. | $24.31 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $23.22 | 2024 | |
| Idorsia Pharmaceuticals US INC | $18.05 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $16.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw In Kwon Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.